| Assessment Status |
Pre-submission consultation scheduled |
| HTA ID |
26051 |
| Drug |
Afamelanotide |
| Brand |
Scenesse® |
| Indication |
Afamelanotide (Scenesse®) is indicated for the prevention of phototoxicity in adult patients with erythropoietic protoporphyria. |
| Rapid review commissioned |
25/09/2026 |
| Rapid review completed |
15/10/2026 |
| Rapid review outcome |
A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of afamelanotide (Scenesse®) for this indication compared with the current standard of care. |
| Full HTA commissioned by the HSE |
16/10/2026 |
